|

JBI-802 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • The Christ Hospital1
  • Jubilant Therapeutics Inc.1

Indications

  • Cancer2
  • Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)1
  • Myeloproliferative Neoplasms (MPN)1
  • Lung Cancer (NSCLC)1
  • Essential Thrombocythemia, ET1

Other1 trial

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Phase 1/2

Cincinnati, Ohio1 trial

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

The Christ Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.